|Dr. Dame Louise Makin MA, Ph.D.(Cantab), MBA, DBE||Chief Exec. Officer & Exec. Director||1.61M||3.86k||56|
|Mr. Rolf Kristian Berndtson Soderstrom BA, ACA||CFO & Exec. Director||981k||9.65k||51|
|Dr. Peter Stratford||Chief Technical Officer and Head of Innovation||N/A||N/A||50|
|Dr. Melanie G. Lee CBE, Ph.D., FMedSci, DSc (Hons)||Chief Scientific Officer||N/A||N/A||59|
|Mr. Andy Burrows||VP of Corp. and Investor Relations||N/A||N/A||N/A|
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and interventional pulmonology products, including PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Specialty Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of envenomations from the copperhead snake; Vistogard for the treatment of 5-fluorouracil toxicity; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup for hip joint replacement; and Lemtrada for treatment of multiple sclerosis. The company also manufactures and commercializes therapeutic ultrasound devices. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
BTG plc’s ISS Governance QualityScore as of August 1, 2017 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 1.